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Abstract: Ceruloplasmin (Cp) concentration and oxidative activity in serum are lowered in 
Parkinson’s disease (PD). In most PD patients, iron increases in the substantia nigra in the 
midbrain. In PD, the low Cp concentration and activity in serum and the high iron amounts 
in the substantia nigra appears to be correlated. An hereditary background is common in PD 
and variations in the Cp gene that have been found in PD are associated with high iron levels 
in the substantia nigra. Variations in Cp synthesis and in the incorporation of copper into the 
Cp molecule are essential features of PD. In Alzheimer’s disease (AD), the Cp activity in serum 
is lowered but not the concentration, except in the advanced stages of the disease. Generally, 
iron is not increased in the AD brain. In the AD brain, iron accumulates in neuritic plaques and 
in neurofibrillary tangles. There is also increased risk of iron-mediated tissue damage, which 
may possibly be counteracted by Cp. At the same time, the AD brain is short in copper, which 
presumably results in the deficient activity of many copper enzymes in the brain, in addition to 
Cp. Lowered Cp activity in serum most likely stems from lessened incorporation of copper in 
the Cp molecule and similar incorporation defects might also apply to other copper enzymes 
in AD.
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Introduction
The role of the oxidative (ferroxidase) activity of the multi-copper enzyme ceruloplasmin 
(Cp) in iron homeostasis was first described around 1970.1 Later experiments in 
mice with disruption of the Cp gene (located on chromosome 3) showed that Cp is 
essential in moving iron out of the reticuloendothelial cells and hepatocytes.2 It was 
subsequently found that Cp exists not only in a free, secreted form but also in a bound, 
glycosylphosphatidylinositol (GPI)-anchored form in astrocytes in the central nervous 
system (CNS). These experiments concluded that GPI-Cp is required for the cellular 
efflux of iron in the CNS and that defects in this activity might lead to the accumulation 
of iron in the brain and result in neurodegenerative lesions.3 Aceruloplasminemia is a 
rare autosomal, recessive disorder in which ceruloplasmin is, as the name indicates, 
missing in serum and in other tissues. In line with this, aceruloplasminemia is 
characterized by impaired iron homeostasis with iron deposits in the brain and other 
organs.4,5 There is considerable evidence that connects Alzheimer’s disease (AD) with 
disturbed iron homeostasis in the brain. Thus, alterations have been found in the normal 
cellular distribution of iron and iron proteins in the AD brain6 and it is hypothesized that 
the aberrant distribution of iron in the AD brain could lead to oxidative damage.7 Also, 
many hereditary causes of disrupted iron homeostasis, including aceruloplasminemia, 
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Table 1 Cp concentration, oxidative activity, and Cp-specific oxidative activity in two studies of PD patients and two studies of AD 
patients compared to healthy and age- and sex-matched controls
Determinations Patients,  
mean (range)
Controls,  
mean (range)
Number  
of pairs
P-values
PD patients (study 1)13
Ceruloplasmin concentration, mg/mL (serum) 342 (160–560) 388 (180–600) 40 0.0006a
Ceruloplasmin oxidative activity, units/mL (serum) 110 (60–193) 139 (65–222) 40 0.0006a
Ceruloplasmin specific oxidative activity, units/mg (serum) 322 (195–515) 362 (202–544) 40 0.0094a
PD patients (study 2; follow-up study)14
Ceruloplasmin concentration, mg/mL (serum) 284 (210–390) 316 (240–460) 28 0.0067b
Ceruloplasmin oxidative activity, units/mL (serum) 94 (42–176) 125 (52–236) 28 0.0024b
Ceruloplasmin specific oxidative activity, units/mg (serum) 325 (173–518) 377 (217–544) 24 0.0291b
AD patients (study 1)15
Ceruloplasmin concentration, mg/mL (serum) 382 (247–562) 383 (222–655) 44 .0.05a
Cp oxidative activity, units/mL (serum) 89 (47–155) 136 (79–227) 26 0.0005a
Cp specific oxidative activity, units/mg (serum) 219 (144–322) 338 (255–442) 26 0.0001a
AD patients (study 2)16
Ceruloplasmin concentration, mg/mL (serum) 225 (100–400) 220 (150–340) 40 .0.05c
Cp oxidative activity, units/mL (serum) 119 (68–201) 136 (69–179) 41 0.0165c
Cp specific oxidative activity, units/mg (serum) 568 (283–1093) 611 (345–814) 40 0.0040c
Notes: The mean values and the range of the individual results and the P-values relevant to comparison of the patient and the control groups are shown. PD study 2 was a 
follow-up study of the 28 patients living (out of 40) 5 years after participating in PD study 1 and their healthy controls. AD study 1 and AD study 2 were independent studies 
12 years apart. In the AD studies, the values for Cp-specific oxidative activity are not comparable between the two rounds. This is due to methodological changes in the 
determination of Cp concentration in serum. awilcoxon’s matched pairs test; bStudent’s t-test; cMann–whitney test.
Abbreviations: AD, Alzheimer’s disease; Cp, ceruloplasmin; PD, Parkinson’s disease.
result in iron depositions in the brain and movement disorders 
that are reminiscent, at least partially, of Parkinson’s disease 
(PD) (reviewed by Ponka8). In PD patients specifically, 
a negative correlation has been found between the Cp 
concentration and the oxidative activity in serum and iron 
deposits in the substantia nigra in the brain.9,10
The gene for apoceruloplasmin is, as mentioned above, 
located on chromosome 3 near the gene areas for transferrin 
and transferrin receptors.11 The gene for the ATPase (ATP7B) 
that is responsible for the incorporation of copper into fully 
developed holoceruloplasmin is located on chromosome 13.12 
Thus, disorders of these two synthetic processes obviously 
have different causes. In the authors’ studies, care was taken 
to determine both Cp parameters in order to elucidate what 
role Cp activity might play, specifically in these diseases.13–16 
The data from the two AD studies and the two PD studies of 
the authors are shown in Table 1.
In this short presentation, based on recent studies, 
the authors elaborate the contention that defective Cp 
mechanisms, which are evident in the serum of AD and PD 
patients, may relate to the etiology of these diseases, although 
they may manifest themselves in iron disorders of the CNS. 
However, a note of caution should be added in this context; 
in the living patient, there is no way of knowing whether 
alterations in Cp parameters in serum correspond to similar 
changes in Cp in the brain.
Ceruloplasmin in serum and iron  
in Parkinson’s disease
PD is primarily a disjunction of dopaminergic neurons located 
in the substantia nigra in the midbrain and neurons in the basal 
ganglia, collectively named the extrapyramidal brain region. 
More iron is found in this region than in any other region 
in the brain. In PD, the dopaminergic neurons of substantia 
nigra degenerate and lose their blackish color, and the iron 
content usually increases further. Inside many of the degener-
ated neurons are amyloid formations, so-called Lewy bodies, 
which bind iron. Lewy bodies consist of many substances. 
In the core of the Lewy body is a protein, α-synnuclein, of 
uncertain biological function, and iron seems to be a requisite 
for its deposition and accumulation. In PD, there is also a loss 
of ferritin in the neurons of the midbrain.17–19 Thus, in PD, 
iron might be deposited in a disorderly manner in extrapy-
ramidal structures, resulting in tissue damage, as is the case 
with neuromelanin, as discussed later.
In the authors’ study on 40 PD patients, the results showed 
that both the Cp concentration and oxidative activity in serum 
were significantly lower than in the age- and sex-matched 
healthy controls.13 Five years later, 28 of the patients were 
still alive and consented to further study. At that point, they 
were the same age as the original group but had progressed 
further in the disease. Results from the latter study were 
identical to the first study.14 Cp-specific activity (oxidative 
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activity related to mass) was calculated. In both studies, the 
Cp-specific activity was significantly lower in the patients 
than in the controls. Thus, the quality of the enzyme must 
have been significantly deteriorated in the patients and this 
can best be explained by lowered incorporation of copper 
into the Cp molecule13,14 (see also Table 1).
Cp is a so-called acute phase reactant. Accordingly, 
serum concentration increases during various conditions 
associated with oxidative stress. In these circumstances, 
the acute increase of Cp concentration is generally ascribed 
to increased transcription of the Cp gene by cytokines, 
especially interleukin-6.11 In healthy persons, increased Cp 
concentration may be matched by increased special activity in 
serum, as is the case in advanced age.20 In disease, increased 
Cp concentration may, on the other hand, represent a 
compensatory mechanism for pathologically low Cp oxidative 
activity.21,22 In the opinion of the authors, this may have been 
the case in Arnal et al.23 These authors found that the Cp 
concentration increases with the deterioration of disease in 
PD patients and, at the same time, observed an increase of 
the free copper (not bound to Cp) in serum. The increase in 
free copper is indicative of a lower incorporation of copper 
into the Cp molecule and, consequently, the lower Cp activity 
was compensated by increased Cp concentration.
Two recent studies have dealt with the relation between 
Cp parameters in serum and iron in the substantia nigra. In 
the first study, by Jin et al,9 iron was determined by magnetic 
resonance in seven brain regions in PD patients. Iron was 
significantly increased in the substantia nigra of these patients 
only if they also had low Cp concentration in serum. In PD 
patients with normal Cp, concentration in serum iron was 
not increased in the substantia nigra, nor was increased iron 
found in other brain regions. Thus, it was concluded from this 
study, that at least two variants of PD might exist: (1) PD with 
high iron in the substantia nigra and low Cp concentration 
in serum, and (2) PD with normal iron in the substantia 
nigra and normal Cp concentration in serum. In the second 
study, by Martinez-Hernandez et al,10 Cp oxidative activity 
in serum was negatively correlated with the iron content of 
the substantia nigra. In this study, increased iron was found 
in the substantia nigra of all patients and the Hoehn and Yahr 
scores were, on average, about the same (2.45 and 2.40, 
respectively) as in the first PD study of the authors.13
In another study, iron was found in pathologically high 
amounts in the substantia nigra of more than 90% of all the 
PD patients studied. Large amounts of iron were also found 
in the substantia nigra of close relatives of the PD patients, 
although only a few of them had manifest symptoms of 
the disease. Moreover, iron was found in large amounts in 
the substantia nigra of a relatively small number of healthy 
persons unrelated to the PD patients.24 Thus, the accumulation 
of iron in the substantia nigra, although common in PD, is 
seemingly not enough in itself to produce the clinical symp-
toms of PD. Extensive research should be instituted in this 
field and especially with a view to detecting possible defects 
in Cp synthesis. In this context, it is of interest that Cp gene 
variations have been associated with iron accumulation in 
the substantia nigra in PD patients.25
The oxidative activity of ceruloplasmin is seemingly 
involved in the oxidation and polymerization of redundant 
catecholamines (dopamine, norepinephrine, epinephrine) 
in neurons where these amines function as transmitter 
substances.26 A common name for these polymerization 
products is neuromelanin. It binds iron and impacts the 
blackish-blue color on catecholaminergic neurons in the 
substantia nigra and locus coerulus in the midbrain and pons. 
By binding iron, neuromelanin obviously has a regulatory 
function in keeping the levels of noxious ferrous iron (Fe2+) 
low in these iron-rich structures. In PD, degenerative or dying 
neurons release neuromelanin (and deplete their color), which 
is digested by microglia. The iron released from neuromelanin 
could subsequently lead to iron-mediated tissue damage.27 Thus, 
it is reasonable to assume that high Cp oxidative activity might 
counteract this process and obviate the occurrence of PD.
Rotenone is an organic substance found in plants (Derris 
root and some other tropical and subtropical plants). It is 
one of several substances that, in experiments with rats and 
mice, was found to induce a condition that could be used 
as a model of PD. Among these substances, rotenone has 
been found to have the most specific effect on dopaminergic 
neurons.28 Rotenone is an inhibitor of NADH dehydrogenase 
in the mitochondria (complex I), which oxidizes NADH to 
NAD. Blocking this enzyme results in deranged electronic 
transport with lowered energy production and increased 
risks of developing noxious oxygen radicals. Dopaminergic 
neurons are especially sensitive to blocking of mitochondrial 
dehydrogenases.28,29
Two things are of special interest in animal studies with 
rotenone: first, rats and mice differ to a high degree in their 
sensitivity to the effect of rotenone; second, in mice at least, 
the difference in sensitivity to rotenone might refer to the 
levels of Cp in the animals.28–30
In summary, in PD, lowered Cp concentration and oxi-
dative activity in serum and increased iron in the substantia 
nigra are often concomitant occurrences. Deranged electronic 
transport and energy production in the mitochondria of nigral 
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dopaminergic neurons may be an important cause of PD, with 
Cp possibly counteracting the process.
Ceruloplasmin in serum and iron  
in Alzheimer’s disease
AD is the most common of the so-called dementias that result 
from the degeneration and death of cortical neurons in the 
brain. Prominent among the neurons that are affected early 
in AD are cholinergic neurons projecting to the hippocam-
pus and hippocampal regions located in the temporal lobe. 
The pathological status in the AD brain is characterized by 
intracellular neurofibrillary tangles and intercellular neuritic 
plaques primarily located near synapses between neurons in 
the affected regions. Neurofibrillary tangles are considered 
to have more prospective value than the neuritic plaques in 
assessing the progress of the disease.18,31
Tau is a neuronal, microtubule-associated protein, the 
physiological function of which is to regulate microtubule 
dynamics.32 In AD, the tau protein is phosphorylated to a 
pathological degree, leading to distortion of the microtubuli 
and splitting of the axonal structures. This results in the 
formation of neurofibrillary tangles.18,31 Thus, deficient 
axonal transport may be the real hallmark of the disease. In 
this context, it is interesting that oligodendrocytes, which are 
responsible for the synthesis of the myelin sheath, contain 
more iron than any other cells in the CNS, and they are 
also considered to put forward most of the transferrin in the 
brain.17,19,33,34
Amyloid precursor protein (APP) is a glycosylated 
 protein of unknown biological function that is uniformly 
found in the membranes of cells in the body, but most 
abundantly in the brain. The protein is cleaved into several 
peptides by the following three intracellular enzymes: 
α-, β-, and γ-secretases. In the CNS, these cleavage products 
might possibly have some regenerating or protecting effect 
on the integrity of synaptic structures. Most of the cleav-
age products are soluble and never accumulate or are found 
in tissue deposits. In AD, however, a less soluble variant, 
a β-peptide with 42 amino acids, is more prevalent. This 
β-peptide constitutes the amyloid core in the neuritic 
plaques. It is usually called Aβ and comprises the essential 
part of the plaques.18,31,35
Iron, along with copper and zinc (released during neural 
transmission), accumulates in the plaques and is, with or 
without the other metals, a requisite for the disposition of 
Aβ in the plaques.18 Iron binding to the hyperphosphorylated 
tau protein is also a precursory pattern to the formation of 
the neurofibrillary tangles.18 Thus, the two most prominent 
pathological features of the AD brain, plaques and tangles, 
are dependent on the presence of iron.17,19
Occurrence of the deleterious Fenton reaction, which is 
dependent on free Fe2+, is often observed in the early stages 
of AD or at the prodromal stage of the disease (mild cognitive 
impairment). The iron-mediated noxious oxidative activity 
in the AD brain is also negatively related to the occurrence 
of the neuritic plaques.36, 37 This is in line with the fact that 
the plaques do not form without iron and, accordingly, may 
have a protective effect in mopping up wayward iron in the 
brain of AD patients. As the iron content in the AD brain is, 
in general, not increased,38 the abnormal iron accumulation in 
neurofibrillary tangles and neuritic plaques must be evidence 
of a dysfunctional status of iron in the brain. On the same 
line, Quintana et al39 hypothesize that, in AD, dysfunctional 
ferritin (representing storage iron) may increase oxidative 
stress due to iron and myelin breakdown, which is also seen 
in old age. In this context, it is of interest that experiments 
with genetically engineered mice indicate that Cp plays an 
important role in protecting the CNS from iron-mediated 
free radical injury.40
The authors determined the Cp concentration and 
oxidative activity in the serum of 44 and 26 AD patients, 
respectively, and in their age- and sex-matched controls. 
These patients had relatively mild disease (mean MMSE 
score 15.9). The Cp concentration was the same in both 
the patient and the control groups, but the Cp activity was 
significantly lower in the patient group.15 A second study 
of the same design was performed 12 years later on 40 AD 
patients with mild disease (mean MMSE score 17.9) and 
their healthy controls. The results of this study were the same 
as in the first study16 (see also Table 1). Taken together, the 
uniform results of the two studies indicate that the Cp activity 
in serum, but not the Cp concentration, is lowered in AD. 
At any rate, this applies to the mild stages of AD and can 
best be explained by decreased incorporation of copper in 
the Cp molecule, while the synthesis of apoceruloplasmin 
is the same in both patients and controls.
Brewer et al41 determined Cp concentration and activity 
in the serum of 31 AD patients with generally mild disease 
(mean MMSE score about 21.5) and their controls. In their 
studies, like the present authors’ study, they found that 
the Cp activity was lowered in the patients but not the Cp 
concentration. At the same time, free copper in plasma (not 
bound to Cp) was significantly increased in the patients. 
Brewer et al explained this by a lower degree of copper 
incorporation into the Cp molecule: “it lacks at least some 
of its coppers.”
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Arnal et al23 determined Cp concentration in serum of 
AD patients on three different stages of the disease (from 
very mild to a severe stage; mean MMSE scores 11.6–
22.2). In the most affected patients, the Cp concentration 
was significantly lower than in their controls but not 
in the two groups of patients that were less affected. 
Therefore, the possibility exists that the Cp concentration 
in serum may also be lower in the AD patients who were 
more heavily affected than in the study of Brewer et al41 
or in the studies of the present authors.15,16 Arnal et al23 
also found that free copper (not bound to Cp) in plasma 
increased in the patients and was negatively correlated 
with the MMSE score.
In experiments with an animal model (rabbits) of AD, 
Sparks and Schreurs found that trace amounts of copper in the 
drinking water of the animals accelerated AD’s pathological 
changes in their brains and induced learning deficits in 
the animals.42 Subsequently, Squitti et al43–45 have argued 
that the level of free copper in plasma of AD patients is a 
predictive value in assessing the progression of the disease. 
The present authors are not aware that Squitti et al have, 
in their studies, also determined the Cp oxidative activity 
in serum along with the Cp concentration. It is, therefore, 
difficult to estimate whether the free copper in plasma in 
their studies was independent of changes in the Cp activity. 
From the study of Brewer et al,41 it can be concluded that an 
increase of free copper in plasma and decreased Cp activity 
in the serum of AD patients are interrelated phenomena. 
Moreover, copper has been found to be significantly lowered 
in the brain of AD patients.38 Until these differences have 
been sorted out, there seems little ground for instituting zinc 
therapy in AD patients in order to lower copper in serum as 
advocated by Hoogenraad.46
Capo et al determined the levels of Cp oxidative activity 
in the cerebrospinal liquor from 10 AD patients and their 
controls. The results showed that Cp oxidative activity was 
significantly lower in the patients, whereas the copper concen-
tration was the same in both groups. The results also showed 
that, normally, a relatively smaller part of the copper in the 
liquor is found bound to Cp than in serum.47 Although this 
finding is at variance with serum in this respect, the results 
indicate that the Cp oxidative activity is also lowered in this 
compartment in AD patients.
In contrast to iron, which is mostly transported bound 
to transferrin from the blood into the brain,20 copper 
most likely diffuses from blood to the brain in the ion-
ized state.48 There is no lack of copper in the serum or 
cerebrospinal liquor of AD patients;15,47,49 thus, in the AD 
brain, the influx, or the efflux, of copper is seemingly 
compromised.
Clearly, the low amount of copper in the AD brain may 
lead to generally lesser synthesis in the brain of many copper 
enzymes besides ceruloplasmin. The superoxide dismutase 
1 (SOD1), which scavenges the superoxide anion radical, is 
a copper enzyme with antioxidative function that is parallel 
to the activity of ceruloplasmin. However, judging from their 
activity in serum and red blood cells, respectively, separate 
processes of copper deprivation may prevail for Cp and 
SOD1. Thus, in the first AD study of the present authors, the 
activity of both enzymes was found significantly lowered in 
the patients, but independently.15 In the second AD study,16 
which was performed 12 years later, determination of SOD1 
was not included as the analytical kit used in the first study 
was no longer available.
In summary, iron is generally not increased in the AD 
brain. It accumulates in neuritic plaques and neurofibrillary 
tangles and can mediate tissue damage, resulting in axonal 
dysfunction and cell death. Cp oxidative activity in serum 
is lowered in AD. Defective incorporation of copper in Cp, 
besides presumptive lack of enzyme copper in AD brain, 
could be an essential feature in AD.
Conclusion
A correlation exists between increased iron in the substantia 
nigra and lowered Cp concentration and activity in the 
serum of PD patients. Variations in the Cp gene have, as 
previously mentioned, been associated with increased iron 
in the substantia nigra and PD.25 It is known that PD often 
has an hereditary basis. In an Icelandic study from 2000, 
it was found that the risk of acquiring PD is much greater 
in persons closely related to PD patients than in unrelated 
persons; at the same time, the risk to patients’ spouses was 
not increased.50 Accordingly, it should be one of the aims 
of future studies in this field to elucidate whether Cp gene 
variations or possible transcription defects are generally 
found in PD patients. Another intriguing and related research 
object is to delineate whether healthy persons with high 
amounts of iron in the substantia nigra are free of such 
deviations or defects.
The newly publicized findings that iron is generally not 
increased in the AD brain and that the brain is at the same 
time short of copper is of great importance. As there is no lack 
of copper in plasma in AD, the signs and symptoms of cop-
per deprivation in the disease would most likely be confined 
to the CNS. To the knowledge of the present authors, 
copper deprivation has not been much studied in humans. 
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In this context, it should be mentioned that, in a 60-year-
old study of Icelandic ewes suffering from heavy copper 
shortage, the most conspicuous pathological defects in the 
brains of their lambs were lesions in neuronal myelin and 
demyelination.51,52 Whether lesions in the iron-rich myelin 
sheath as envisaged by Texel et al33 might contribute to the 
pathological distribution of iron in the AD brain is at present 
an open question. At any rate, future studies on Cp in AD 
should also include research on other copper enzymes, which 
could further illuminate the pathogenesis of the disease. 
SOD1 was already mentioned above; another important 
copper enzyme is the multi-copper oxidase hephaestin. 
 Hephaestin is a Cp homolog and is essential for the absorption 
of iron from the gastrointestinal tract, but it is also found with 
Cp in the cortical areas of the brain that are most affected 
in AD.33 Other proteins, like APP and the prion protein that 
are biologically connected with iron and copper and which 
may possess relevant enzymatic activities, should also be 
scrutinized in future studies on AD.35
In contrast to PD, variations in the Cp gene have not 
been described in adult-onset AD.53 However, variations 
in the Cp gene or in the incorporation of copper in the 
Cp molecule might, if found, also be of importance in the 
etiology of AD.
In conclusion, defective Cp activity and concentration in 
serum are seemingly related to the occurrence of PD, and defec-
tive Cp activity in serum, along with defects in other copper 
enzymes, is possibly of importance in the etiology of AD.
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